SE8204382L - Sett att framstella malcellysfaktor och anvendning derav - Google Patents

Sett att framstella malcellysfaktor och anvendning derav

Info

Publication number
SE8204382L
SE8204382L SE8204382A SE8204382A SE8204382L SE 8204382 L SE8204382 L SE 8204382L SE 8204382 A SE8204382 A SE 8204382A SE 8204382 A SE8204382 A SE 8204382A SE 8204382 L SE8204382 L SE 8204382L
Authority
SE
Sweden
Prior art keywords
human
tclf
ebv
cell lines
factor
Prior art date
Application number
SE8204382A
Other languages
English (en)
Swedish (sv)
Other versions
SE8204382D0 (sv
Inventor
M Mitsuhashi
H Ohnishi
Original Assignee
Hayashibara Biochem Lab
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP56112913A external-priority patent/JPS5816687A/ja
Priority claimed from JP56112914A external-priority patent/JPS5815921A/ja
Priority claimed from JP56120459A external-priority patent/JPS5821621A/ja
Priority claimed from JP56187626A external-priority patent/JPS5889195A/ja
Priority claimed from JP56187627A external-priority patent/JPH0764744B2/ja
Priority claimed from JP56205115A external-priority patent/JPS6011890B2/ja
Application filed by Hayashibara Biochem Lab, Mochida Pharm Co Ltd filed Critical Hayashibara Biochem Lab
Publication of SE8204382D0 publication Critical patent/SE8204382D0/xx
Publication of SE8204382L publication Critical patent/SE8204382L/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8204382A 1981-07-21 1982-07-19 Sett att framstella malcellysfaktor och anvendning derav SE8204382L (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP56112913A JPS5816687A (ja) 1981-07-21 1981-07-21 リンホトキシンの製造方法
JP56112914A JPS5815921A (ja) 1981-07-21 1981-07-21 抗リンホトキシン感受性疾患剤
JP56120459A JPS5821621A (ja) 1981-07-31 1981-07-31 ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JP56187626A JPS5889195A (ja) 1981-11-21 1981-11-21 標的細胞障害性因子の製造方法
JP56187627A JPH0764744B2 (ja) 1981-11-21 1981-11-21 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
JP56205115A JPS6011890B2 (ja) 1981-12-21 1981-12-21 ツモアネクロシスフアクタ−の製造方法

Publications (2)

Publication Number Publication Date
SE8204382D0 SE8204382D0 (sv) 1982-07-19
SE8204382L true SE8204382L (sv) 1983-01-22

Family

ID=27552385

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8204382A SE8204382L (sv) 1981-07-21 1982-07-19 Sett att framstella malcellysfaktor och anvendning derav
SE9000532A SE9000532L (sv) 1981-07-21 1990-02-14 Farmaceutisk tclf-komposition

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9000532A SE9000532L (sv) 1981-07-21 1990-02-14 Farmaceutisk tclf-komposition

Country Status (9)

Country Link
US (1) US4495282A (de)
AT (1) AT387980B (de)
AU (1) AU560793B2 (de)
CH (1) CH664974A5 (de)
DE (1) DE3227262C3 (de)
FR (1) FR2513124B1 (de)
GB (1) GB2106117B (de)
IT (1) IT1196549B (de)
SE (2) SE8204382L (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4806471A (en) * 1982-09-16 1989-02-21 A/S Alfred Benzon Plasmids with conditional uncontrolled replication behavior
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS6019720A (ja) * 1983-07-14 1985-01-31 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子およびその製造法
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
DE3483252D1 (de) * 1983-12-05 1990-10-25 Asahi Chemical Ind Verfahren zur induktion von antitumorimmunozyten, verfahren zur herstellung von antitumorimmunozyten und durch das verfahren hergestellte antitumorimmunozyten.
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
HU192254B (en) * 1983-12-13 1987-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing human leucocite and human gamma interferons in consecutive steps
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JPS6124520A (ja) * 1984-07-12 1986-02-03 Takeshi Makitsubo 腫瘍壊死因子様物質を抽出する方法
GB2161813B (en) * 1984-07-20 1988-07-13 Michiko Koga Anti-tumor agent
US5840522A (en) * 1984-09-20 1998-11-24 Chiron Corporation Recombinant lectins
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4752575A (en) * 1984-11-26 1988-06-21 The Regents Of The University Of California Lymphotoxins with antitumor activity and method for producing same
EP0216786B1 (de) * 1984-12-21 1992-03-18 Biogen, Inc. Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren
PT81823B (pt) * 1985-01-14 1987-11-30 Yamanouchi Pharma Co Ltd Metodo de preparacao de factores endogenos humanos reguladores de cancro
EP0216934A4 (de) * 1985-03-04 1987-07-09 Sawai Seiyaku Kk Neues tumor-nekrosis-faktor-induzierendes mittel mit ursprung aus säurebeständigen bakterien.
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4770995A (en) * 1985-08-29 1988-09-13 New York Blood Center, Inc Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4777242A (en) * 1986-10-10 1988-10-11 Phillips Petroleum Company Purification of recombinant tumor necrosis factor
US5213970A (en) * 1987-01-23 1993-05-25 Board Of Regents, The University Of Texas System Method for obtaining soluble antitumor factor
US4975377A (en) * 1987-05-14 1990-12-04 Key Marc E Cell growth chambers and method of use thereof
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
WO1990000400A1 (en) * 1988-07-15 1990-01-25 The Trustees Of Columbia University In The City Of New York Tumor necrosis enhancing factor and methods of preparation and use
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7179891B2 (en) 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
JP4177604B2 (ja) * 2002-03-25 2008-11-05 株式会社林原生物化学研究所 生理活性複合体
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
CA2508375C (en) * 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
US10436680B2 (en) 2013-10-15 2019-10-08 Kianoosh Peyvan Capture, disruption, and extraction apparatus and method
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
WO2017197331A2 (en) 2016-05-13 2017-11-16 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
CN108576399A (zh) * 2018-03-22 2018-09-28 中国农业科学院生物技术研究所 复合干扰素组合物及其制剂和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
DE2961658D1 (en) * 1978-05-17 1982-02-18 Thomae Gmbh Dr K Process for preparing human interferon
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
JPS55154919A (en) * 1979-05-24 1980-12-02 Hayashibara Takeshi Preparation of interferon
US4328207A (en) * 1979-12-27 1982-05-04 Ken Hayashibara Process for preparing mouse interferon
JPS586475B2 (ja) * 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
JPS5743696A (en) * 1980-08-27 1982-03-11 Hayashibara Biochem Lab Inc Preparation of human luteinizing hormone

Also Published As

Publication number Publication date
SE9000532L (sv) 1991-08-15
GB2106117B (en) 1985-06-12
CH664974A5 (fr) 1988-04-15
DE3227262A1 (de) 1983-03-03
IT8248855A0 (it) 1982-07-20
DE3227262C3 (de) 1996-03-21
IT1196549B (it) 1988-11-16
DE3227262C2 (de) 1988-11-17
AU560793B2 (en) 1987-04-16
FR2513124B1 (fr) 1989-11-17
AU8620082A (en) 1983-01-27
GB2106117A (en) 1983-04-07
SE8204382D0 (sv) 1982-07-19
ATA283582A (de) 1988-09-15
US4495282A (en) 1985-01-22
AT387980B (de) 1989-04-10
FR2513124A1 (fr) 1983-03-25
SE9000532D0 (sv) 1990-02-14

Similar Documents

Publication Publication Date Title
SE8204382L (sv) Sett att framstella malcellysfaktor och anvendning derav
Goldstein Isolation of bovine thymin: a polypeptide hormone of the thymus
ZA867347B (en) Medicaments to combat chronic graft-versus-host diseases and to combat autoimmune diseases,in particular systemic lupus erythematosus
ES509706A0 (es) "mejoras introducidas en el objeto de la patente principal n 504.302".
DE3485759D1 (de) Reinigung von rekombinanten interleukin-2.
FI883688A (fi) Molekylaer kloning och expression av humant interleukin-3.
FR2561940B1 (fr) Dispositif de recuperation des organismes vivants sur les filtres rotatifs de stations de pompage d'eau
DE3583258D1 (de) Schwimmbadwasserbehandlung.
GB2083836A (en) Monoclonal antibody
JPS5562024A (en) Preventive and remedy for interferon-sensitive disease
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
FI946202A (fi) Fluoria sisältäviä dipeptidejä inhibiittoreina ihmisen lenkosyyttielastaasi-inhibiittoreita vastaan
Low et al. Thymosin and other thymic hormones and their synthetic analogues
Murphy et al. The turnover catabolism and excretion of folate administered at physiological concentrations in the rat
IT8148649A0 (it) Procedimento per la produzione di nuovi mutanti di virus di herpessimplex tipo 1 e tipo 2
ES2128313T3 (es) Naftalimidas n-substituidas, su obtencion y empleo.
EP0026561A3 (de) Nephritogenische Verbindungen, die ein biologisch aktives Kohlehydratteil enthalten, Verfahren zu ihrer Herstellung und ihre Verwendungen
IT1195296B (it) Procedimento per la produzione di globulina antilinfociti tipo t
ATE346921T1 (de) Menschliches, durch kalzium aktivierbares kaliumkanalpolypeptid aus leukozyten
FI914160A0 (fi) Analysis och behandling av auto- immuniska sjukdomar.
MACHIDA et al. Disseminated type mineralization in the Tochibora ore deposits, Kamioka mine, Gifu prefecture
FR2381743A1 (fr) Aryl-2 arylidene-6 (aminoalcoxy substitue)-1 cyclohexenes-1, leur procede de preparation et leur utilisation therapeutique comme anti-inflammatoires
FR2597502B1 (fr) Procede de fabrication d'alcool avec recuperation des vinasses issues de la distillation
JPS56164117A (en) Useful substance and its preparation

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8204382-9